SUPN:NAS (USA) Also trade in: Germany UK

Supernus Pharmaceuticals Inc

$ 36.3 0.23 (0.64%)
Volume: 404,721 Avg Vol (1m): 608,582
Market Cap $: 1.90 Bil Enterprise Value $: 1.87 Bil
P/E (TTM): 17.61 P/B: 4.32
Earnings Power Value 12.86
Net Current Asset Value -0.58
Tangible Book 7.79
Projected FCF 18.32
Median P/S Value 53.67
Graham Number 19.01
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 1.08
Equity-to-Asset 0.46
Debt-to-Equity 0.73
Debt-to-EBITDA 1.99
Interest Coverage 7.98
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.64
DISTRESS
GREY
SAFE
Beneish M-Score -2.29
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 32.87%
WACC 9.03%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 35.33
Net Margin % 27.14
ROE % 29.44
ROA % 13.86
ROC (Joel Greenblatt) % 2456.50
3-Year Total Revenue Growth Rate 40.50
3-Year Total EBITDA Growth Rate 101.20
3-Year EPS w/o NRI Growth Rate 94.20

» SUPN's 30-Y Financials

Financials (Next Earnings Date: 2019-05-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SUPN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare BOM:532296 XTER:EVT TSE:4521 SZSE:300199 SZSE:000078 SHSE:600277 SHSE:600267 SZSE:002907 SHSE:603707 NAS:HZNP SZSE:002390 HKSE:00460 XLJU:KRKG SHSE:600216 NAS:MDCO NAS:HRTX TSE:4540 SHSE:600380 NAS:IRWD SHSE:603367
Traded in other countries S49.Germany 0LB2.UK
Address 1550 East Gude Drive, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Ratios

Current vs industry vs history
PE Ratio (TTM) 17.61
Forward PE Ratio 15.34
N/A
PE Ratio without NRI 17.61
Price-to-Owner-Earnings 18.20
PB Ratio 4.32
PS Ratio 4.78
Price-to-Free-Cash-Flow 15.32
Price-to-Operating-Cash-Flow 15.23
EV-to-EBIT 11.86
EV-to-EBITDA 11.31
EV-to-Revenue 4.57
Current Ratio 3.06
Quick Ratio 2.90
Days Inventory 499.14
Days Sales Outstanding 91.87
Days Payable 75.94

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.66
Price-to-Projected-FCF 1.98
Price-to-Median-PS-Value 0.68
Price-to-Graham-Number 1.91
Earnings Yield (Joel Greenblatt) % 8.44

More Statistics

Revenue (TTM) (Mil) $ 408.9
EPS (TTM) $ 2.06
Beta 1.1
Volatility % 51.38
52-Week Range $ 30.05 - 61.25
Shares Outstanding (Mil) 52.32

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N